Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Metformin/teneligliptin - Handok Pharmaceuticals

Next Previous
Drug Profile

Metformin/teneligliptin - Handok Pharmaceuticals

Alternative Names: HL1511; Metformin/MP-513; MP-513/metformin; Tenelia M SR; Teneligliptin/metformin

Latest Information Update: 27 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Handok Inc
  • Class Antihyperglycaemics; Biguanides; Ketones; Piperazines; Pyrazoles; Small molecules; Thiazolidines
  • Mechanism of Action AMP activated protein kinase stimulants; Dipeptidyl peptidase 4 inhibitors; Gluconeogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 27 Jun 2019 Chemical structure information added
  • 31 Dec 2014 Preregistration for Type-2 diabetes mellitus in South Korea (PO, 1000mg/20mg) (Mitsubishi Tanabe Pharma pipeline, February 2015)
  • 30 Nov 2014 Preregistration for Type-2 diabetes mellitus in South Korea (PO, 500mg/10mg) (Mitsubishi Tanabe Pharma pipeline, February 2015)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top